emas-online.orgEuropean Menopause and Andropause Society | EMAS

Login Access EMAS Membership Search Search Home About EMAS Membership Journals Junior Section JuMP programme Travel grant Research grant Svg Vector Icons : http://www.onlinewebfonts.com/icon What we do Upcoming webinars Webinars on-demand Podcasts Menopause in the Workplace Menopause training for HCPs EMAS School Research updates News Guidelines and education Congresses / Courses Viatris – EMAS 2023 Contact Login Access EMAS Membership Twitter Linkedin Youtube With an active worldwide membership and over 40 affiliated societies, the European Menopause and Andropause Society (EMAS) is the key international society promoting health in women and men at midlife and beyond. In our menopause-focused activities, we are committed to ensuring equality, diversity, and inclusion, as we strive to promote better health and well-being during this significant life stage. Learn moreMenopause Education: Webinars and Podcasts for All! Join the EMAS community! Linkedin Twitter Youtube EMAS is partnered with Newsletter Subscribe to the EMAS Newsletter Join our Newsletter to receive the latest updates Subscribe Don’t miss it Menopause and women’s health: Events Thursday 27 Jun 28 Jun British Menopause Society (BMS) 33rd Annual Scientific Conference 8 a.m. Warwickshire, United Kingdom Register Wednesday 11 Sep 14 Sep 2024 NAMS Annual Meeting 8 a.m. Chicago, USA Register Monday 30 Sep 03 Oct 7th International Clinical Trials Methodology Conference 8 a.m. Edinburgh, UK Register Check out Menopause and women’s health: Latest activities EMAS News Webinars Podcasts EMAS Position Statement | Thyroid disease and Menopause Read More Margaret Rees, EMAS executive director, receives accolade from The Open University Read More EMAS Position Statement | Testosterone Replacement Therapy in Older Men Read More View All News English Spanish Mandarin Portuguese Ukrainian Russian View All Videos EMAS/ESE Webinar Part 2: Menopause Relive the enlightening discussions from Part 2 of our webinar series on Menopause, chaired by Irene Lambrinoudaki and Antoan… EMAS/ESE Webinar Part 1: Fertility in late reproductive age Relive the insightful sessions from Part 1 of our webinar series on Fertility in Late Reproductive Age, chaired by… Personalized oral combined MHT and long-term effects: How to choose according to the patient’s needs (EN) Join renowned experts Dr. Larysa Mishchenko (Ukraine) and Dr. Suvarna Khadilkar (India) in an insightful webinar exploring the nuances… Personalized oral combined MHT and long-term effects: How to choose according to the patient’s needs (ES) Practical Aspects of MHT: Regimen, dosage, duration of treatment, and adverse events handling (ES) Menopause beyond hot flushes: How to address common symptoms in the Asian population? (ES) Personalized oral combined MHT and long-term effects: How to choose according to the patient’s needs (CN) Practical Aspects of MHT: Regimen, dosage, duration of treatment, and adverse events handling (CN) Menopause beyond hot flushes: How to address common symptoms in the Asian population? (CN) Personalized oral combined MHT and long-term effects: How to choose according to the patient’s needs (PT) Practical Aspects of MHT: Regimen, dosage, duration of treatment, and adverse events handling (PT) Menopause beyond hot flushes: How to address common symptoms in the Asian population? (PT) Personalized oral combined MHT and long-term effects: How to choose according to the patient’s needs (UA) Practical Aspects of MHT: Regimen, dosage, duration of treatment, and adverse events handling (UA) Menopause beyond hot flushes: How to address common symptoms in the Asian population? (UA) Personalized oral combined MHT and long-term effects: How to choose according to the patient’s needs (RU) Practical Aspects of MHT: Regimen, dosage, duration of treatment, and adverse events handling (RU) Menopause beyond hot flushes: How to address common symptoms in the Asian population? (RU) Abnormal uterine bleeding in perimenopause – How to manage it? (Chinese Version) November 8, 2023 No Comments EMAS Podcast Abnormal uterine bleeding in perimenopause – How to manage it? (Chinese Version) Play Episode Pause Episode Mute/Unmute Episode Rewind 10 Seconds 1x Fast Forward 30 seconds 00:00 / 10:00 Share Share Link Embed Abnormal uterine bleeding in perimenopause – How to manage it? (English Version) November 8, 2023 No Comments EMAS Podcast Abnormal uterine bleeding in perimenopause – How to manage it? (English Version) Play Episode Pause Episode Mute/Unmute Episode Rewind 10 Seconds 1x Fast Forward 30 seconds 00:00 / 10:01 Share Share Link Embed Host: Welcome to today’s podcast Abnormal uterine bleeding in perimenopause – How to manage it? . This episode is part of a podcast series supported by Abbott. The content is solely the responsibility of EMAS, the European Menopause and Andropause Society . All our episodes are available in English, Spanish, Mandarin, and Russian and you can find them on any of the most popular podcast platforms. In today’s episode Prof. Natalia Pedachenko , Head of Obstetrics, Gynecology and Perinatology Department at Shupyk National Healthcare University of Ukraine; Gynecologist at Kiyv Maternity Hospital #1 and Executive Secretary of the Ukrainian Society of Gynecologists Endocrinologists will help us understand how to manage abnormal uterine bleeding in perimenopausal women. Prof. Natalia Pedachenko : Greetings, dear colleagues, and thank you for your kind attention. At the beginning. I would like to note that for all women with abnormal uterine bleeding, we should apply the classification of possible causes of these bleedings developed by Figo in 2018, which uses a very clear and easy mnemonic palm coin. Next, I would like to divide the women with abnormal uterine bleeding in the perimenopausal age into two, let’s say, conditional groups. Those who do not use hormonal drugs and those who are on menopausal hormonal therapy. Let’s begin with the first. Women at the age of 45, 47, often have heavy menstrual bleedings, which are associated with ovulation disturbances or anovulation or organic pathology, which significantly impair the quality of life. Hormonal preparations are widely used in the treatment of abnormal uterine bleeding, in particular combined oral contraceptives, COCs, and levonorgestrel intrauterine device (52 milligrams). COCs can be used in women who do not want to use an intrauterine device or have contraindications to its application. The combination of estradiol valerate and dienogest in a dynamic dosage regimen is the only combined oral contraceptive which has approved indication for the treatment of abnormal uterine bleeding. So, this combination may be the drug of choice in women with abnormal uterine bleeding. The dynamic dosing regimen of COCs with estradiol valerate is associated with relatively stable estrogen levels throughout the cycle, which allows for a positive effect on vasomotor symptoms and mood lability, provides a woman’s body with natural estrogen, characterized by minimal effect, metabolic and hemostatic parameters. In addition, this combination may have an advantage in women with sexual desire dysfunction, including those when taking other combined oral contraceptives. Levonorgestrel intrauterine device (52 milligrams) is recommended by many clinical guidelines in different countries of the world as the first-line therapy of abnormal uterine bleeding as it is the most effective treatment method compared to other medical options. Levonorgestrel intrauterine device, (52 milligrams), reduces the volume of menstrual blood loss by 97%. Helps to increase the level of hemoglobin and ferritin, thereby improving the quality of life in women with abnormal uterine bleeding. Today, there are studies that confirm the effectiveness of its use in women with abnormal uterine bleeding caused by adenomyosis and uterine myoma. Recently, data on its positive effect in the prevention of recurrence of endometrial...